The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Anti-tumour antibodies

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. 

Anti-tumour antibodies is a key innovation area in immuno-oncology 

Monoclonal antibodies (mAbs) are immune system proteins that are created in the lab. MAbs, like all antibodies, contain a highly specific binding site that enables attachment to specific antigens. Mabs for cancer therapy typically bind to antigens which are expressed on the surface of tumour cells. mAbs can be used in their simple form or can be used to make other mAb-based therapeutics including, antibody-drug conjugates (ADCs), bispecific antibodies, and nanobodies.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-tumour antibodies. 

Key players in anti-tumour antibodies – a disruptive innovation in the pharmaceutical industry  

 ‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators. 

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. 

Patent volumes related to anti-tumour antibodies

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 1153 Unlock company profile
Gilead Sciences 291 Unlock company profile
Daiichi Sankyo 249 Unlock company profile
Pfizer 235 Unlock company profile
Amgen 206 Unlock company profile
Bristol-Myers Squibb 199 Unlock company profile
AbbVie 176 Unlock company profile
ImmunoGen 168 Unlock company profile
Seagen 166 Unlock company profile
Astellas Pharma 161 Unlock company profile
Immatics 159 Unlock company profile
Toray Industries 157 Unlock company profile
AstraZeneca 129 Unlock company profile
Stemcentrx 112 Unlock company profile
Sorrento Therapeutics 110 Unlock company profile
Oxford BioTherapeutics 103 Unlock company profile
ADC Therapeutics 75 Unlock company profile
TRON gGmbH 70 Unlock company profile
C. H. Boehringer Sohn 69 Unlock company profile
Alethia Biotherapeutics 69 Unlock company profile
Merck & Co 63 Unlock company profile
Memorial Sloan Kettering Cancer Center 63 Unlock company profile
Chiome Bioscience 60 Unlock company profile
Sesen Bio 60 Unlock company profile
GSK 57 Unlock company profile
Jiangsu Hengrui Medicine 54 Unlock company profile
Eureka Therapeutics 51 Unlock company profile
Regeneron Pharmaceuticals 43 Unlock company profile
National Research Council of Canada 43 Unlock company profile
Molecular Templates 42 Unlock company profile
Adicet Bio 41 Unlock company profile
Centre National de la Recherche Scientifique 41 Unlock company profile
OBI Pharma 38 Unlock company profile
Helix BioPharma 36 Unlock company profile
National Cancer Center 36 Unlock company profile
United States Of America 34 Unlock company profile
TRACON Pharmaceuticals 33 Unlock company profile
Sanofi 31 Unlock company profile
Celldex Therapeutics 26 Unlock company profile
Les Laboratoires Servier 25 Unlock company profile
Merus 24 Unlock company profile
Revitope Oncology 23 Unlock company profile
Singh Molecular Medicine 23 Unlock company profile
Zymeworks 23 Unlock company profile
Fujifilm Holdings 23 Unlock company profile
Eli Lilly and 23 Unlock company profile
Development Center for Biotechnology 22 Unlock company profile
Oncomatryx Biopharma 22 Unlock company profile
Singh Biotechnology 22 Unlock company profile
JSR 21 Unlock company profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche is one of the leading patent filers in the field of anti-tumour antibodies. It is investigating multiple mAb therapeutics, which are in various stages of development. Genentech (subsidiary of F. Hoffmann-La Roche) entered an agreement with Biogen to develop and commercialise mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for the treatment of B-cell non-Hodgkin’s lymphoma and other cancer indications.

Some other key patent filers in the anti-tumour antibody area include Gilead Sciences, Daiichi Sankyo, Pfizer, Amgen, and Bristol-Myers Squibb.

In terms of application diversity, TRACON Pharmaceuticals is the top company followed by AstraZeneca and Development Center for Biotechnology. By geographic reach, Singh Molecular Medicine holds the top position. Singh Biotechnology and Centre National de la Recherche Scientifique are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.